West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 18 4 2017 04 01 Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer 1151 1156 46013 10.22034/APJCP.2017.18.4.1151 EN Wirsma Arif Harahap Surgical Oncology Division Faculty of Medicine Universitas Andalas/ Dr. M Djamil General Hospital Padang, West Sumatera Province, Indonesia. 0000-0002-0356-5424 A Ramadhan Surgical Oncology Division Faculty of Medicine Universitas Andalas/ Dr. M Djamil General Hospital Padang, West Sumatera Province, Indonesia. Daan Khambri Surgical Oncology Division Faculty of Medicine Universitas Andalas/ Dr. M Djamil General Hospital Padang, West Sumatera Province, Indonesia. Samuel Haryono Surgical Oncology Division Faculty of Medicine Universitas Andalas/ Dr. M Djamil General Hospital Padang, West Sumatera Province, Indonesia. 0000-0002-6655-0633 Ricvan Dana Nindrea Surgical Oncology Division Faculty of Medicine Universitas Andalas/ Dr. M Djamil General Hospital Padang, West Sumatera Province, Indonesia. Journal Article 2017 03 16 Objective: The aim of this study is to determine the outcome of trastuzumab therapy for 6 or 12 months in patients with HER2 positive operable breast cancer who followed the national health insurance system in Indonesia. Methods: Data were extracted from medical records of Dr. M Djamil General Hospital Padang and Dharmais Cancer Hospital/ National Cancer Center Jakarta for post-operative breast HER-2 positive cancer patients treated with trastuzumab for 6 or 12 months who had been followed up for at least 5 years (January 1st in 2010 until December 31st in 2015). Disease free survival and overall survival rates and their relationship with trastuzumab duration was investigated using survival analysis (the Kaplan-Meier method and log rank test). Data were analyzed using the STATA program. Results: A total of 121 women fulfilled the criteria of the study, 80 who had received trastuzumab for 6 months and 41 patients who received 12 months’ therapy. Disease free survival was 54 months (95% CI 45-63) compared with 63 months (95% CI 54-72), respectively. The log-rank test p value was 0.048 so the 12 months’ treatment regime did result in a significantly lower probability of recurrence compared with the 6 months’ regime (HR = 2.6). Analysis of the overall survival rate revealed median survival of 57 months (95% CI 49-64) for 6 months’ therapy compared to 62 months (95% CI 53-72) for 12 months. However, the log-rank test p value of 0.073 indicated that the extra six months of therapy did not decrease the probability of death (HR = 2.4). Conclusion: Trastuzumab therapy for 12 months reduced the recurrence rate in post-operative breast HER-2 positive cancer patients but did not significantly reduce mortality.

https://journal.waocp.org/article_46013_700a0523fc616ac833294fe03aeb5d58.pdf